Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent deals with Chiron, Human Genome Sciences and NeuTec Pharma highlight Novartis’ strategic priorities.

You may also be interested in...



Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Head of firm’s research arm discusses Novartis’ drug discovery model, a growing pipeline of biologics and the company’s partnering strategy.

Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Head of firm’s research arm discusses Novartis’ drug discovery model, a growing pipeline of biologics and the company’s partnering strategy.

Genentech VP-Business Development Joseph McCracken: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)

Partnership with Roche has been the "ultimate win/win deal," McCracken says.

Related Content

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel